Language Barriers Linked to Cancer Treatment Delays
-
By
-
Andrea Surnit
-
June 12, 2026
-
4 min
By
Andrea Surnit
June 12, 2026
"The more AI changes what we do … the less able we are to check it.”
by Lisa Astor
October 1, 2026
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.
August 31, 2026